Abstract
Abstract
Introduction
Diffuse-type gastric cancer (DTGC) is associated with poor outcome. Surgical resection margin status (R) is an important prognostic factor, but its exact impact on DTGC patients remains unknown. The aim of this study was to assess the prognostic value of microscopically positive margins (R1) after gastrectomy on survival and tumour recurrence in DTGC patients.
Methods
All consecutive DTGC patients from two tertiary centers who underwent curative oncologic gastrectomy from 2005 to 2018 were analyzed. The primary endpoint was overall survival (OS) for R0 versus R1 patients. Secondary endpoints included disease-free survival (DFS), recurrence patterns as well as the overall survival benefit of chemotherapy in this DTGC patient cohort.
Results
Overall, 108 patients were analysed, 88 with R0 and 20 with R1 resection. Patients with negative lymph nodes and negative margins (pN0R0) had the best OS (median 102 months, 95% CI 1–207), whereas pN + R0 patients had better median OS than pN + R1 patients (36 months 95% CI 13–59, versus 7 months, 95% CI 1–13, p < 0.001). Similar findings were observed for DFS. Perioperative chemotherapy offered a median OS of 46 months (95% CI 24–68) versus 9 months (95% CI 1–25) after upfront surgery (p = 0.022). R1 patients presented more often early recurrence (< 12 postoperative months, 30% vs 8%, p = 0.002), however, no differences were observed in recurrence location.
Conclusion
DTGC patients with microscopically positive margins (R1) presented poorer OS and DFS, and early tumour recurrence in the present series. R0 resection should be obtained whenever possible, even if other adverse biological features are present.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference46 articles.
1. Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. The Lancet 393(10184):1948–1957. https://doi.org/10.1016/S0140-6736(18)32557-1
2. Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N et al (2019) Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20(7):e368–e377. https://doi.org/10.1016/S1470-2045(19)30318-3
3. Aurello P, Magistri P, Nigri G, Petrucciani N, Novi L, Antolino L et al (2014) Surgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 management. Anticancer Res 34(11):6283–6288
4. Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S (2014) Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. World J Gastroenterol WJG 20(19):5679–5684. https://doi.org/10.3748/wjg.v20.i19.5679
5. Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG (2013) Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol 20(8):2663–2668. https://doi.org/10.1245/s10434-013-2950-5